Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Brain Neoplasms 1050Glioblastoma 920Glioma 603Central Nervous System Neoplasms 436Astrocytoma 396Gliosarcoma 339Neuroblastoma 325Oligodendroglioma 255Neoplasms 181Medulloblastoma 165Breast Neoplasms 154Sarcoma 114Recurrence 108Ependymoma 105Neoplasm Metastasis 95Meningioma 91Melanoma 88Lymphoma 87Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Neurofibromatosis 1 79Wilms Tumor 75Osteosarcoma 69Head and Neck Neoplasms 69Ovarian Neoplasms 68Testicular Neoplasms 67Lymphoma, Non-Hodgkin 67Burkitt Lymphoma 66Familial ependymoma 63

Interventions

fludarabine 1Leukapheresis 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cytokine Release Syndrome × CNS × Clear all
NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡